Adaptimmune Therapeutics Plc (ADAP) | Stock Price, Analysis, News, Fundaments & Technical Information

stock

Adaptimmune Therapeutics Plc

NASDAQ | ADAP

0.24

USD

-0.0018 (-0.75%)

AT CLOSE (AS OF Apr 17, 2025)

$61M

MARKET CAP

P/E Ratio

-0.3

EPS

$1.5

52 Week High

$0.2

52 Week Low

LIFE SCIENCES

Sector

ADAP Chart

Area

Trade Smarter

Take control of your trading journey with a set of smart tools for serious trades

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Learn More About Backtests

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Learn More About Scanner

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Learn More About Signals

Journal

Record your trades and performance to improve your trading with AfterPullback’s Trading Journal

Learn More About Journal

ADAP Technicals

Tags:

ADAP Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	$178M
Total Revenue	$178M
Cost Of Revenue	$70K
Costof Goods And Services Sold	$70K
Operating Income	-$69M
Selling General And Administrative	$81M
Research And Development	$149M
Operating Expenses	$247M
Investment Income Net	-
Net Interest Income	$3.2M
Interest Income	$6.6M
Interest Expense	$3.3M
Non Interest Income	-
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	$11M
Income Before Tax	-$67M
Income Tax Expense	$3.6M
Interest And Debt Expense	-
Net Income From Continuing Operations	-$71M
Comprehensive Income Net Of Tax	-
Ebit	-$64M
Ebitda	-$53M
Net Income	-$71M

Revenue & Profitability

Earnings Performance

ADAP Financials

Highlights

Balance Sheet

Cash Flow

Income Statement

Yearly

Quarterly

yearly Balance Sheet (As of Dec 31, 2024)

Field	Value (USD)
Total Assets	$246M
Total Current Assets	$188M
Cash And Cash Equivalents At Carrying Value	$91M
Cash And Short Term Investments	$91M
Inventory	$7.3M
Current Net Receivables	-
Total Non Current Assets	$58M
Property Plant Equipment	-
Accumulated Depreciation Amortization Ppe	-
Intangible Assets	$3.9M
Intangible Assets Excluding Goodwill	$3.9M
Goodwill	-
Investments	-
Long Term Investments	-
Short Term Investments	$60M
Other Current Assets	$28M
Other Non Current Assets	-
Total Liabilities	$234M
Total Current Liabilities	$65M
Current Accounts Payable	-
Deferred Revenue	-
Current Debt	-
Short Term Debt	$4.7M
Total Non Current Liabilities	$170M
Capital Lease Obligations	$24M
Long Term Debt	$50M
Current Long Term Debt	-
Long Term Debt Noncurrent	-
Short Long Term Debt Total	$24M
Other Current Liabilities	$39M
Other Non Current Liabilities	$4.3M
Total Shareholder Equity	$12M
Treasury Stock	-
Retained Earnings	-$1.1B
Common Stock	$2.1M
Common Stock Shares Outstanding	$1.5B

yearly Cash Flow (As of Dec 31, 2024)

Field	Value (USD)
Operating Cashflow	-$73M
Payments For Operating Activities	-
Proceeds From Operating Activities	-
Change In Operating Liabilities	-
Change In Operating Assets	-
Depreciation Depletion And Amortization	$11M
Capital Expenditures	$2.7M
Change In Receivables	-
Change In Inventory	-$7.4M
Profit Loss	-
Cashflow From Investment	-
Cashflow From Financing	$79M
Proceeds From Repayments Of Short Term Debt	-
Payments For Repurchase Of Common Stock	-
Payments For Repurchase Of Equity	-
Payments For Repurchase Of Preferred Stock	-
Dividend Payout	-
Dividend Payout Common Stock	-
Dividend Payout Preferred Stock	-
Proceeds From Issuance Of Common Stock	-
Proceeds From Issuance Of Long Term Debt And Capital Securities Net	-
Proceeds From Issuance Of Preferred Stock	-
Proceeds From Repurchase Of Equity	-
Proceeds From Sale Of Treasury Stock	-
Change In Cash And Cash Equivalents	-
Change In Exchange Rate	-
Net Income	-$71M

yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	$178M
Total Revenue	$178M
Cost Of Revenue	$70K
Costof Goods And Services Sold	$70K
Operating Income	-$69M
Selling General And Administrative	$81M
Research And Development	$149M
Operating Expenses	$247M
Investment Income Net	-
Net Interest Income	$3.2M
Interest Income	$6.6M
Interest Expense	$3.3M
Non Interest Income	-
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	$11M
Income Before Tax	-$67M
Income Tax Expense	$3.6M
Interest And Debt Expense	-
Net Income From Continuing Operations	-$71M
Comprehensive Income Net Of Tax	-
Ebit	-$64M
Ebitda	-$53M
Net Income	-$71M

ADAP News

ADAP Profile

Adaptimmune Therapeutics Plc Profile

Sector: LIFE SCIENCES

Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to solid tumor patients in the United States and the United Kingdom. The company is headquartered in Abingdon, the United Kingdom.

Symbol	Price	Change %	Market Cap	Volume
DMN	$0.00	9.68%	-	409,386,220
STSS	$0.03	20.75%	$522.68K	391,799,240
NVDA	$101.49	-2.87%	$2.48T	292,517,465
HTZ	$8.24	44.31%	$2.54B	266,908,117
FMTO	$0.02	-35.81%	$2.41M	198,396,141

Symbol	Price	Change %	Market Cap	Volume
LLY	$839.96	14.30%	$754.27B	10,853,385
PG	$170.63	2.55%	$400.10B	7,227,061
JNJ	$157.47	2.31%	$379.48B	10,981,067
ABBV	$172.99	0.76%	$306.02B	8,998,056
NVO	$58.08	-7.63%	$282.79B	32,220,629

Symbol	Price	Change %	Market Cap	Volume
MSGM	$2.75	145.54%	$8.75M	36,058,545
SXTC	$2.16	118.42%	$29.73M	51,508,885
ADGM	$1.78	92.81%	$54.65M	114,733,769
PNBK	$3.28	73.55%	$13.04M	1,511,087
RTC	$0.37	72.09%	$10.86M	187,018,434

Symbol	Price	Change %	Market Cap	Volume
JEWL	$0.00	-90.83%	$2.78M	470,134
LXEH	$6.84	-70.25%	$26.82M	1,373,607
PKBO	$0.02	-67.86%	$531.87K	66,140
TCBP	$0.50	-67.53%	$360.37K	1,955,586
MMV	$0.48	-51.02%	$11.90M	1,568,644

Quick Links

ADAP $0.24 (-0.75%) Quote details